Current treatment of metastatic endometrial cancer

Cancer Control. 2009 Jan;16(1):38-45. doi: 10.1177/107327480901600106.


Background: Endometrial cancer is the most common gynecologic malignancy. The majority of patients have disease confined to the uterus and have an excellent overall prognosis. However, subgroups of patients have advanced primary disease or recurrences following primary treatment.

Methods: The management of metastatic disease is variable, depending on factors such as comorbidities, tumor grade, performance status, and prior treatments. Management options include hormonal therapy and cytotoxic chemotherapy, as well as targeted therapies that inhibit angiogenesis and the cellular signaling pathways involved in cell growth and proliferation. A comprehensive review of these treatments for metastatic endometrial cancer was conducted and is discussed.

Results: Hormonal therapy and cytotoxic chemotherapy have traditionally been used in the treatment of metastatic endometrial cancer. Advances in molecular biology have led to multiple potential targeted therapies to be used in the treatment of metastatic endometrial cancer.

Conclusions: While several treatment modalities are now available to treat patients who present with metastatic endometrial cancer, overall prognosis remains poor.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Delivery Systems
  • Endometrial Neoplasms / drug therapy*
  • Endometrial Neoplasms / pathology*
  • Female
  • Humans
  • Neoplasm Metastasis / drug therapy*
  • Neoplasm Metastasis / pathology*


  • Antineoplastic Agents